Negotiation and Selling Skills: MMS Semester-I Presentation on the pharma Industry in India

1. Indian
Pharma Industry
Student’s Name: Pranav Gaggar (69)
Nandini Sabban (101)
Nikita Daki (64)
Pradnya bodke (62)
Vivek Vaity (112)
Sunny Amin (58)
Professor Name: Prof.Iftiqar Mistry

2. Introduction:
 India is the largest provider of generic drugs globally. India enjoys an
important position in the global pharmaceuticals sector.
 The history of Indian pharmaceutical market in 1970’s was almost non-
existent. Today, India has gained immense importance & carved a niche for
itself in the pharmaceutical industry.
 Indian pharmaceutical sector industry supplies over 50 per cent of global
demand for various vaccines, 40 per cent of generic demand in the US and 25
per cent of all medicine in UK
 India is the 3rd largest player in the world with 500 different APS & ranks
fourth globally in terms of production volumes, & 13th globally in domestic
consumption value.
 Presently over 80% of the antiretroviral drugs used globally to combat AIDS
(Acquired Immune Deficiency Syndrome) are supplied by Indian
pharmaceutical firms.

3. Major Players:
Sun Pharmaceuticals Cipla Lupin Pharmaceuticals
• Leading pharma company in
India in 2017 as per Moving
Annual Turnover (MAT)
• World's fifth largest specialty
generic pharmaceutical
company
• Serves over 150 markets across
the world
• More than 2,000 marketed
products
• More than 40 manufacturing
sites
• In FY19, total income of the
company reached Rs 30,091.40
crore (US$ 4.33 billion) and in
Q1FY20 it stood at Rs 8,587.38
crore (US$ 1.22 billion)
• Leading global pharmaceutical
company
• More than 1,500 products various
therapeutic categories
• Second largest pharma company in
India in 2017 as per Moving Annual
Turnover (MAT)
• Over 43 state-of-the-art
manufacturing facilities for API
and formulations
• Ranked amongst the top 10 most
dispensed generic companies in
North America
• Amongst the top 10 generic
companies in the world
• Fifth largest pharma company in
India in 2017 as per Moving Annual
Turnover (MAT)
• 18 manufacturing sites
• Products sold in more than 100
countries

4. Advantage India:

5. SWOT Analysis:
• Other low cost countries affecting
demand
• Government regulations changing
• Expanding of Drugs Price Control
Order
• Lack of investment in infrastructure
• Wage inflation
• R & D restricted by lack outdated
patient office
• Counterfeiting threat
•Increase in per capita income
•Global demand for generics rising
•Increasing health insurance sector
•Significant investment from MNCs
•Medical tourism
•Cheap, diverse clinical trials
•Global outstanding hub due to low
cost of skilled labour
•Stringent pricing regulations
•Poor transport & medical
infrastructure
•Lack of data protection
•Very competitive environment
•Poor health insurance coverage
•Production of low quality drugs
tarnishes image of industry abroad
•Low investment in innovative R & D
•Low cost of skilled manpower
•Access to large pool of highly
trained scientists
•Strong marketing & distribution
network
•Proven track record in design of
high technology manufacturing
devices
•Low cost of innovation,
manufacturing & operation
Strengths Weaknesses
ThreatsOpportunities

6. Market Size of Pharma industry
• The pharmaceutical sector was valued at US$ 33 billion in 2017. The country’s
pharmaceutical industry is expected to expand at a CAGR of 22.4 per cent over 2015–20 to
reach US$ 55 billion. India’s pharmaceutical exports stood at US$ 17.27 billion in FY18 and
have reached US$ 19.14 billion in FY19.
• India's biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-
agriculture, bio-industry and bioinformatics is expected grow at an average growth rate of
around 30 per cent a year and reach US$ 100 billion by 2025.

7. Conclusion:
 The pharmaceutical industry has been around for over a century and has
improved drastically to where it is today.
 This industry is present to benefit individuals who need medications & it’s
best to be sure each drug distributed is safe & effective.
 Although this field does have challenges, in the future research will be done
to overcome these challenges & to better the pharmaceutical industry.
 With the large concentration of multi national pharmaceutical companies in
India, it becomes easier to attract foreign direct investment.
 Pharmacy is needed in the United States daily, whether to cure the common
cold or to treat a life- threatening illness.

8. Thanking you…